1. Switzerland Stocks

  2. •

    Healthcare

  3. •

    Medical - Distribution
DocMorris AG

DocMorris AG

ROSE.SW
DocMorris AGCH flagSwiss Exchange
35.02
CHF
- -
- -
404.49MMarket Cap
DocMorris AG
ROSE.SW
(Swiss Exchange)

Recent

price

35.02

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
FRC
- -
53.02
75.3
80.66
132.45
133.22
121.04
95.49
92.76
93.63
77.04
80.13
88.14
42.54
40.89
42.47
Revenue per Share
- -
0.43
1.34
0.95
-2.25
1.04
0.5
-1.39
-3.42
-3.02
-2.98
-7.36
-11.52
-7.82
3.47
-4.06
Basic EPS, GAAP
- -
0.95
-0.04
2.44
-1.26
-1.26
0.53
-3.66
-4.14
-5.02
-7.05
-6.91
-9.91
-6.57
-5.01
-2.31
Free Cash Flow per Basic Share
- -
0.62
0.58
0.23
0.22
- -
0.28
0.18
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
6.45
10.38
11.17
8.19
8.96
9.23
6.35
3.38
1.06
9.99
6.16
-4.1
-8.19
-3.83
-6.34
Book Value per Share
- -
5.36
8.16
5.51
3.35
3.94
2.76
4.42
13.84
13.88
-3.39
-3.95
-5.64
-10.11
-2.72
-6.45
Tangible Book Value per Share
- -
9
6
6
7
7
7
9
11
13
18
18
20
22
24
24
Basic Weighted Avg Shares
- -
488
487
523
911
916
834
880
983
1,207
1,356
1,477
1,727
931
969
1,017
Sales/Revenue/Turnover
- -
1.43
0.85
0.42
-0.68
0.85
0.96
-0.86
-3.94
-2.76
-4.76
-8
-11.33
-16.2
-8.52
-10.25
Operating Margin (%)
- -
7
5
5
8
9
7
9
17
19
32
39
51
40
43
46
Depreciation Expense
- -
4
9
6
-15
7
3
-13
-36
-39
-52
-136
-226
-171
82
-97
Net Income, GAAP
- -
22.69
- -
6.29
- -
- -
14.79
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
0.8
1.78
1.17
-1.7
0.78
0.41
-1.45
-3.69
-3.23
-3.86
-9.19
-13.07
-18.38
8.49
-9.56
Profit Margin (%)
34
31
28
91
63
61
54
21
154
298
215
383
325
155
113
97
Working Capital
8
6
- -
77
58
58
62
9
3
116
349
520
520
493
236
308
LT Debt
90
79
82
86
73
77
73
104
294
444
406
532
485
351
431
340
Total Equity
- -
4.63
- -
1.51
- -
- -
4.61
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
5.74
- -
5.75
- -
- -
4.5
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
6.46
13.71
8.8
-24.03
12.14
5.5
-20.91
-76.86
-157.58
-55.26
-93.81
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
25.88%
-0.72%
-21%
Free Cash Flow
-104.08%
-8.36%
-53.51%
Net Income, GAAP
-46.18%
-32.99%
-218.2%
Sales/Revenue/Turnover
3.22%
-2.24%
4.91%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
969
2024
- -
- -
- -
- -
1,017
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
3.47
2024
- -
- -
- -
- -
-4.06
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Patterson Companies, Inc. (PDCO)
DocCheck AG (AJ91.DE)
Cowealth Medical Holding Co., Ltd. (4745.TWO)
IVD Medical Holding Limited (1931.HK)
160 Health International Ltd. (2656.HK)
China National Accord Medicines Corporation Ltd. (200028.SZ)
Business
DocMorris AG DocMorris AG (ROSE.SW), Europe's leading online pharmacy operator, provides e-commerce pharmacy services, marketplace platforms, and professional healthcare solutions across Germany, the Netherlands, Spain, France, Switzerland, and other European markets; its core offerings encompass prescription medicines (Rx), over-the-counter (OTC) drugs, consumer health products, beauty and personal care (BPC) items, nutritional supplements, painkillers, first aid products, and private-label brands, delivered primarily from a highly automated logistics center in Heerlen, Netherlands, with capacity exceeding 27 million parcels annually. The company sells to private individuals and online mail-order pharmacies under prominent brands including DocMorris, PromoFarma by DocMorris, and TeleClinic, a telemedicine platform connecting patients with over 1,500 doctors for more than 1.6 million treatments; it also extends professional services to pharmaceutical companies via digital health hubs like DocMorris Ratgeber, health insurers through medication management, automated prescribing, direct billing, and pharmaceutical advice, and marketplace partners numbering over 1,500 pharmacies and sellers for assortment expansion and same-day DocMorris Express delivery. Founded in 1993 by Walter Oberhänsli and headquartered in Frauenfeld, Switzerland, DocMorris AG employs around 1,600 people and generated external revenue of CHF 1,085 million in 2024, serving over 10 million active customers. In May 2023, the company rebranded from Zur Rose Group AG following the sale of its Swiss wholesale business to Migros/Medbase, sharpening focus on digital health ecosystems; more recently, it completed a CHF 208 million rights offering in May 2025 to fuel medium-term Rx growth, incremental marketing, and potential repayment of a CHF 95 million convertible bond due September 2026, alongside refinancing a prior CHF 122 million bond in April 2024 and securing gematik approval for e-prescription redemption via health cards. DocMorris continues accelerating Rx revenue at 52% growth rates into 2025, bolstered by CardLink integrations in apps like medpex and Apotal, while achieving non-Rx profitability in Germany through enhanced margins, retail media scale, private labels, and operational efficiencies.